808 related articles for article (PubMed ID: 27297021)
1. In vitro and in vivo uptake studies of PAMAM G4.5 dendrimers in breast cancer.
Oddone N; Lecot N; Fernández M; Rodriguez-Haralambides A; Cabral P; Cerecetto H; Benech JC
J Nanobiotechnology; 2016 Jun; 14(1):45. PubMed ID: 27297021
[TBL] [Abstract][Full Text] [Related]
2. Transcorneal iontophoresis of dendrimers: PAMAM corneal penetration and dexamethasone delivery.
Souza JG; Dias K; Silva SA; de Rezende LC; Rocha EM; Emery FS; Lopez RF
J Control Release; 2015 Feb; 200():115-24. PubMed ID: 25553828
[TBL] [Abstract][Full Text] [Related]
3. Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.
Liu J; Liu J; Chu L; Wang Y; Duan Y; Feng L; Yang C; Wang L; Kong D
Int J Nanomedicine; 2010 Dec; 6():59-69. PubMed ID: 21289982
[TBL] [Abstract][Full Text] [Related]
4. Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes.
Muñoz AM; Fragoso-Vázquez MJ; Martel BP; Chávez-Blanco A; Dueñas-González A; R García-Sánchez J; Bello M; Romero-Castro A; Correa-Basurto J
Anticancer Agents Med Chem; 2020; 20(15):1857-1872. PubMed ID: 32324521
[TBL] [Abstract][Full Text] [Related]
5. α-Tocopherol Succinate-Anchored PEGylated Poly(amidoamine) Dendrimer for the Delivery of Paclitaxel: Assessment of in Vitro and in Vivo Therapeutic Efficacy.
Bhatt H; Kiran Rompicharla SV; Ghosh B; Biswas S
Mol Pharm; 2019 Apr; 16(4):1541-1554. PubMed ID: 30817166
[TBL] [Abstract][Full Text] [Related]
6. Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin.
Sadekar S; Thiagarajan G; Bartlett K; Hubbard D; Ray A; McGill LD; Ghandehari H
Int J Pharm; 2013 Nov; 456(1):175-85. PubMed ID: 23933439
[TBL] [Abstract][Full Text] [Related]
7. Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycaemia and restore impaired blood-brain barrier permeability in streptozotocin diabetes in rats.
Karolczak K; Rozalska S; Wieczorek M; Labieniec-Watala M; Watala C
Int J Pharm; 2012 Oct; 436(1-2):508-18. PubMed ID: 22721855
[TBL] [Abstract][Full Text] [Related]
8.
Wei X; Liu Z; Zhao Z
Hell J Nucl Med; 2019; 22(1):78-79. PubMed ID: 30968863
[TBL] [Abstract][Full Text] [Related]
9. Development of 99mTc(CO)₃-dendrimer-FITC for cancer imaging.
Tassano MR; Audicio PF; Gambini JP; Fernandez M; Damian JP; Moreno M; Chabalgoity JA; Alonso O; Benech JC; Cabral P
Bioorg Med Chem Lett; 2011 Sep; 21(18):5598-601. PubMed ID: 21778055
[TBL] [Abstract][Full Text] [Related]
10. Improved tumor targetability of Tat-conjugated PAMAM dendrimers as a novel nanosized anti-tumor drug carrier.
Yan C; Gu J; Hou D; Jing H; Wang J; Guo Y; Katsumi H; Sakane T; Yamamoto A
Drug Dev Ind Pharm; 2015 Apr; 41(4):617-22. PubMed ID: 24564798
[TBL] [Abstract][Full Text] [Related]
11. Cellular uptake of glucoheptoamidated poly(amidoamine) PAMAM G3 dendrimer with amide-conjugated biotin, a potential carrier of anticancer drugs.
Uram Ł; Szuster M; Filipowicz A; Zaręba M; Wałajtys-Rode E; Wołowiec S
Bioorg Med Chem; 2017 Jan; 25(2):706-713. PubMed ID: 27919613
[TBL] [Abstract][Full Text] [Related]
12. Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
Jiang G; Li R; Tang J; Ma Y; Hou X; Yang C; Guo W; Xin Y; Liu Y
Oncol Rep; 2017 Feb; 37(2):995-1001. PubMed ID: 28035395
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
14. Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.
Iacobazzi RM; Porcelli L; Lopedota AA; Laquintana V; Lopalco A; Cutrignelli A; Altamura E; Di Fonte R; Azzariti A; Franco M; Denora N
Int J Pharm; 2017 Aug; 528(1-2):485-497. PubMed ID: 28624661
[TBL] [Abstract][Full Text] [Related]
15. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer.
Liu Y; Ng Y; Toh MR; Chiu GNC
J Control Release; 2015 Dec; 220(Pt A):438-446. PubMed ID: 26551345
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.
Kirkpatrick GJ; Plumb JA; Sutcliffe OB; Flint DJ; Wheate NJ
J Inorg Biochem; 2011 Sep; 105(9):1115-22. PubMed ID: 21704583
[TBL] [Abstract][Full Text] [Related]
17. Dendrimer encapsulated and conjugated delivery of berberine: A novel approach mitigating toxicity and improving in vivo pharmacokinetics.
Gupta L; Sharma AK; Gothwal A; Khan MS; Khinchi MP; Qayum A; Singh SK; Gupta U
Int J Pharm; 2017 Aug; 528(1-2):88-99. PubMed ID: 28533175
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates.
Khandare J; Kolhe P; Pillai O; Kannan S; Lieh-Lai M; Kannan RM
Bioconjug Chem; 2005; 16(2):330-7. PubMed ID: 15769086
[TBL] [Abstract][Full Text] [Related]
19. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
20. Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications.
Navath RS; Menjoge AR; Wang B; Romero R; Kannan S; Kannan RM
Biomacromolecules; 2010 Jun; 11(6):1544-63. PubMed ID: 20415504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
